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Reduced renal function may 
explain the higher prevalence 
of hyperuricemia in older people
Yutang Wang1,8,9*, Wanlin Zhang2,8, Tingting Qian3, Hui Sun2, Qun Xu2, Xujuan Hou4, 
Wenqi Hu4, Guang Zhang4, Grant R. Drummond5, Christopher G. Sobey5, Fadi J. Charchar1, 
Jonathan Golledge6,7 & Guang Yang2,9*
This study aimed to investigate the contribution of renal dysfunction to enhanced hyperuricemia 
prevalence in older people. A cohort of 13,288 Chinese people aged between 40 and 95 years were 
recruited from January to May 2019. Serum uric acid concentration and estimated glomerular 
filtration rate [eGFR] were measured. The associations between age or eGFR and serum uric acid or 
hyperuricemia were analyzed using linear or binary logistic regression adjusting for risk factors. Uric 
acid concentration and prevalence of hyperuricemia were greater in older participants. Adjustment 
for reduced renal function (eGFR < 60 mL/min/1.73  m2) eliminated the associations between older age 
and higher uric acid concentration and between older age and higher prevalence of hyperuricemia 
diagnosis, whereas adjustment for other risk factors did not change those associations. Lower eGFR 
was associated with higher uric acid concentration both before (β = − 0.296, P < 0.001) and after 
adjustment for age (β = − 0.313, P < 0.001). Reduced renal function was associated with hyperuricemia 
diagnosis both before (odds ratio, OR, 3.64; 95% CI 3.10–4.28; P < 0.001) and after adjustment 
for age (adjusted OR, 3.82; 95% CI 3.22–4.54; P < 0.001). Mean serum uric acid and prevalence of 
hyperuricemia were higher in people with eGFR < 60 mL/min/1.73 m2 than those with eGFR ≥ 60 mL/
min/1.73  m2. The prevalence of reduced renal function increased with older age (P < 0.001). This study 
suggests that reduced renal function can explain the increased uric acid levels and hyperuricemia 
diagnoses in older people.
Uric acid is the end product of metabolic breakdown of purine  compounds1. Its concentration in serum is a bal-
ance between its production, which is catalyzed by xanthine  oxidase2, and excretion mainly via the  urine3. High 
circulating uric acid (hyperuricemia) has been reported to be associated with many health problems such as 
 hypertension4,5, metabolic  syndrome6, coronary artery  disease7,  stroke8 and  preeclampsia9 and kidney  disease10–12 
which may be associated with the pro-inflammatory effect of uric  acid13.
A number of factors can affect serum uric acid levels. For example, renal dysfunction can impair the excretion 
of uric acid and thus can increase serum uric acid level leading to  hyperuricemia14. Dietary and behavioral factors 
including higher meat consumption, drinking, smoking, less sleep, and sedentary lifestyle can raise serum uric 
acid  levels14–18. In addition, male sex, higher BMI, higher total cholesterol, higher triglyceride, hypertension, 
and diabetes are common risk factors for  hyperuricemia14–17.
It has been reported that serum uric acid and the prevalence of hyperuricemia increase in aged Chinese 
 people19,20. Similar findings are also reported in people from other countries such as  Austria21 and United 
 States22. However, the reasons underlying these observations are  unknown23. This study aimed to investigate 
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the contribution of renal dysfunction to higher uric acid levels and enhanced hyperuricemia prevalence in older 
people using a large Chinese cohort (N = 13,288). We hypothesized that older age is associated with both higher 
uric acid levels and higher prevalence of hyperuricemia, and that adjustment for reduced renal function would 
eliminate those positive associations.
Results
The characteristics of the cohort. A total of 13,288 participants including 7782 men and 5506 women 
aged 40–95 years were included (Table 1). Among these participants, 13.9% were hyperuricemic and 5.5% had 
reduced renal function (eGFR < 60 mL/min/1.73 m2). No participants were on uric acid lowering or dialysis 
therapies.
Uric acid concentration and prevalence of hyperuricemia are greater in older partici-
pants. Older age was associated with higher serum uric acid (β = 0.026, P = 0.003, Table 2) and higher preva-
lence of hyperuricemia diagnosis (OR, 1.007; 95% CI 1.002–1.011; P < 0.005, Table 3). A 10-year increase in age 
Table 1.  Characteristics of the study participants. BMI, body mass index; eGFR, estimated glomerular 
filtration rate; IQR, interquartile range; NA, not applicable; FPG, fasting plasma glucose; TC, total 
cholesterol; TG, triglyceride. a Compared between men and women. The Mann Whitney U was used for 
continuous variables and Fisher’s exact test was used for categorical variables. b Hyperuricemia was defined 
as uric acid ≥ 7 mg/dL for men and ≥ 6 mg/dL for women. c Hypertension was defined as systolic blood 
pressure ≥ 140 mm Hg or diastolic blood pressure ≥ 90 mm Hg. d Reduced renal function was defined as 
eGFR < 60 mL/min/1.73 m2.
Total Men Women P  valuea
Sample size 13,288 7.782 5.506 NA
Age, median (IQR), y 53 (46–61) 53 (46–61) 53 (46–61) 0.089
Serum uric acid, Median (IQR), mg/dL 5.21 (4.36–6.18) 5.81 (5.04–6.67) 4.44 (3.80–5.11)  < 0.001
Hyperuricemiab, % 13.9 17.9 8.2  < 0.001
Hypertensionc, % 40.4 46.2 32.2  < 0.001
eGFR, median (IQR), mL/min/1.73 m2 79.5 (71.1–89.0) 78.6 (70.5–87.3) 81.0 (72.0–90.9)  < 0.001
Reduced renal  functiond, % 5.5 5.9 4.9 0.018
BMI, median (IQR), kg/m2 25.1 (23.0–27.3) 25.8 (24.0–27.8) 23.9 (22.0–26.1)  < 0.001
FPG, median (IQR), mmol/L 5.25 (4.89–5.83) 5.35 (4.95–6.01) 5.13 (4.80–5.59)  < 0.001
TG, median (IQR), mmol/L 1.25 (0.89–1.79) 1.36 (0.97–1.94) 1.13 (0.81–1.58)  < 0.001
TC, median (IQR), mmol/L 4.85 (4.29–5.48) 4.77 (4.23–5.37) 4.99 (4.40–5.65)  < 0.001
Table 2.  Association between age and serum uric acid using linear regression analysis. a Adjusted for reduced 
renal function (estimated glomerular filtration rate rate < 60 mL/min/1.73 m2). b Adjusted for sex, fasting 
glucose, hypertension, body mass index, total cholesterol, and triglycerides. c Adjusted for sex, fasting glucose, 
hypertension, body mass index, total cholesterol, and triglycerides in addition to reduced renal function.
β P value
Univariable 0.026 0.003
Multivariablea − 0.018 0.048
Multivariableb 0.026  < 0.001
Multivariablec − 0.010 0.187
Table 3.  Association between age and hyperuricemia using binary logistic regression analysis. a Adjusted for 
reduced renal function (estimated glomerular filtration rate rate < 60 mL/min/1.73 m2). b Adjusted for sex, 
fasting glucose, hypertension, body mass index, total cholesterol, and triglycerides. c Adjusted for sex, fasting 
glucose, hypertension, body mass index, total cholesterol, and triglycerides in addition to reduced renal 
function.
OR P value
Univariable 1.007 (1.002–1.011) 0.005
Multivariablea 0.996 (0.996–0.991) 0.114
Multivariableb 1.011 (1.005–1.016)  < 0.001
Multivariablec 1.001 (0.995–1.006) 0.810
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of participants was associated with a mean increase in uric acid of 0.03 mg/dL and with a 7% increased risk of 
hyperuricemia. Mean serum uric acid increased from 5.28 mg/dL in 40–49 years of age to 5.47 mg/dL in the 
80–95 years age group (Fig. 1a) and the prevalence of hyperuricemia increased from 13.5% in the 40–49 years of 
age group to 18.6% in the 80–95 years age group (Fig. 1b).
The effect of renal function on associations between age with uric acid concentration and 
hyperuricemia. After adjusting for reduced renal function, older age was no longer associated with higher 
serum uric acid; rather it was associated with a lower serum uric acid concentration (β = − 0.018, P = 0.048, 
Table 2). Mean uric acid in people without reduced renal function decreased from 5.26 mg/dL in the 40–49 years 
age group to 5.11 mg/dL in the 80–95 years age group (Fig. 1a). Adjusting for other risk factors for hyperurice-
mia did not change the association between older age and higher serum uric acid (Table 2). In addition, after 
adjusting for reduced renal function, older age was no longer associated with a higher risk for hyperuricemia 
(P = 0.114, Table 3). After the exclusion of reduced renal function, the prevalence of hyperuricemia no longer 
increased with older age (Fig. 1b). Adjusting for other risk factors for hyperuricemia did not change the associa-
tion between older age and enhanced prevalence of hyperuricemia diagnosis (Table 3). These results suggest that 
reduced renal function explains the increased serum uric acid concentration and prevalence of hyperuricemia 
in aged people.
Reduced renal function is associated with higher uric acid concentration and higher hyper-
uricemia diagnosis independent of age. eGFR was negatively associated with uric acid concentration 
across all participants (β = − 0.296, P < 0.001). A 10 mL/min/1.73  m2 decrease in eGFR of participants was associ-
ated with a mean increase of 0.28 mg/dL in uric acid. The association was independent of age alone (β = − 0.313, 
P < 0.001) or age together with other risk factors for hyperuricemia including sex, fasting glucose, hypertension, 
Figure 1.  Uric acid concentration and prevalence of hyperuricemia across age groups in 13,288 participants. 
(a) Uric acid concentration and (b) prevalence of hyperuricemia across age groups in all participants (filled 
triangles) or participants with (filled circles) or without reduced renal function (open circles). Reduced renal 
function was defined as estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73  m2. Data represent 
mean ± SE. The difference in the prevalence of hyperuricemia among age groups was analyzed by the chi-square 
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body mass index, total cholesterol, and triglycerides (β = − 0.243, P < 0.001). Consistently, people with reduced 
renal function had higher serum uric acid compared to those with preserved renal function (median [interquari-
cle range], 6.15 [5.15–7.14] mg/dL versus 5.17 [4.32–6.12] mg/dL, P < 0.001).
When eGFR was treated as a continuous variable, higher eGFR was associated with a lower risk for hyper-
uricemia diagnosis (OR, 0.956; 95% CI 0.952–0.959; P < 0.001), such that a 10 mL/min/1.73 m2 increase in eGFR 
was associated with a 44% decreased risk of hyperuricemia. The association between higher eGFR and lower 
prevalence of hyperuricemia diagnosis remained after adjusting for age alone (OR, 0.987; 95% CI 0.982–0.992; 
P < 0.001) or age together with other risk factors for hyperuricemia including sex, fasting glucose, hypertension, 
body mass index, total cholesterol, and triglycerides (OR, 0.955; 95% CI 0.950–0.959; P < 0.001).
When eGFR was treated as a categorical variable (< 60 or ≥ 60 mL/min/1.73 m2), reduced renal function 
(< 60 mL/min/1.73 m2) was associated with higher prevalence of hyperuricemia diagnosis (OR, 3.64; 95% CI 
3.10–4.28; P < 0.001). The association remained after adjustment for age alone (OR, 3.82; 95% CI 3.22–4.54; 
P < 0.001) or age together with other risk factors for hyperuricemia including sex, fasting glucose, hyperten-
sion, body mass index, total cholesterol, and triglycerides (OR, 3.37; 95% CI 2.82–4.04; P < 0.001), meaning that 
reduced renal function increased the prevalence of hyperuricemia diagnosis independent of age.
Further sub-analysis was conducted in which eGFR was divided into three categories, i.e. ≥ 60, < 60 and ≥ 30, 
and < 30 mL/min/1.73  m2. Compared to people with an eGFR ≥ 60 mL/min/1.73  m2, people with an eGFR 
between 30 to 60 mL/min/1.73  m2 had an increased risk of hyperuricemia (OR, 3.57; 95% CI 3.03–4.21; P < 0.001), 
and people with an eGFR < 30 mL/min/1.73  m2 had a much higher risk of hyperuricemia (OR, 7.74; 95% CI 
2.98–20.09; P < 0.001). The association remained after adjustment for age, sex, fasting glucose, hypertension, 
body mass index, total cholesterol, and triglycerides.
Gender-based sub-analysis showed that eGFR (as a continuous variable) was negatively associated uric acid 
concentration in both men and women before (β = − 0.285, P < 0.001 for men; β = − 0.308, P < 0.001 for women) 
and after adjustment for age, fasting glucose, hypertension, body mass index, total cholesterol, and triglycerides 
(β = − 0.283, P < 0.001 for men; β = − 0.271, P < 0.001 for women). Reduced renal function (< 60 mL/min/1.73 m2) 
increased both serum uric acid and prevalence of hyperuricemia in both men and women (Fig. 2). Binary logistic 
regression analysis confirmed that reduced renal function was associated with higher prevalence of hyperurice-
mia diagnosis in both men and women before (Men: OR, 3.02; 95% CI 2.47–3.68; P < 0.001. Women: OR, 5.46; 
95% CI 4.12–7.28; P < 0.001) and after adjustment for age, fasting glucose, hypertension, body mass index, total 
cholesterol, and triglycerides (Men: adjusted OR, 3.49; 95% CI 2.81–4.35; P < 0.001. Women: adjusted OR, 2.84; 
95% CI 2.06–3.92; P < 0.001).
The prevalence of reduced renal function increases with older age. The prevalence of reduced 
renal function increased with age in the whole cohort and within each gender (Table 4).
Discussion
This study demonstrates that serum levels of uric acid and the prevalence of hyperuricemia are associated with 
older age and this positive association disappears after adjusting for reduced renal function, but not for other 
risk factors for hyperuricemia. These results suggest that reduced renal function explains the higher uric acid 
levels and enhanced prevalence of hyperuricemia diagnosis in older people.
Renal dysfunction can impair the excretion of uric acid and increase its serum level leading to  hyperuricemia14. 
The current study found that lower eGFR was associated with higher serum uric acid and higher hyperuricemia 
diagnosis, independent of age and other risk factors. Consistent with the literature report 24, this study found 
that the percentage of people with reduced renal function increased with age. Therefore, increased prevalence of 
reduced renal function appears to be the underlying mechanism of the increased prevalence of hyperuricemia 
in aged people.
It was usually thought that the increase in circulating uric acid would lead to a corresponding worsening of 
renal function. However, very recent evidence showed that uric acid-lowering therapy did not slow the decline in 
renal function in patients with chronic kidney  disease25 or with type 1  diabetes26, nor did it produce benefits on 
kidney  failure27, indicating that hyperuricemia is not a cause of chronic kidney disease. Instead, these reports and 
our study suggest that the progression of chronic kidney disease is the cause of the increase in circulating uric acid.
This study showed that circulating uric acid levels in people with preserved renal function showed a gender-
dependent pattern: a gradual decrease over time in men aged over 40 years versus an increase in women dur-
ing the transition from 40–49 years to 50–59 years. The underlying mechanism is unknown. Changes in sex 
hormones over time may result in this gender-dependent pattern. Estradiol can inhibit xanthine  oxidase28, the 
key enzyme in the uric acid production pathway; whereas testosterone can stimulate the  enzyme29. Uric acid-
inhibitory estradiol decreases in women at menopause and uric acid-stimulatory testosterone in men decreases 
gradually after 40  years30. The pattern of changes in those sex hormones seems to mirror the pattern of changes in 
uric acid observed in our study. However, whether this explanation is true needs to be investigated in the future.
A strength of this study is the large sample size that included subjects spanning several decades of older 
people which allowed the analysis of the effect of reduced renal function on the association between older age 
and hyperuricemia. This study has several limitations. First, we did not investigate dietary or behavioral risk 
factors such as higher meat consumption, drinking, higher alcohol intake, smoking, less sleeping, and sedentary 
 lifestyle14–18 which may raise serum uric acid levels of the participants. Second, the results in this study concern 
the inhabitants of eastern and central Asia, and future studies will clarify whether our results apply to people of 
other ethnicities, e.g. Caucasians.
In conclusion, this study found that higher prevalence of reduced renal function appears likely to be respon-
sible for the increase in serum uric acid in aged people.
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Methods
Subjects. A total of 13,288 participants aged 40 years or more underwent a health examination between 
January and May 2019 at the Health Physical Examination Center of the First Affiliated Hospital of Shandong 
First Medical University, Jinan, Shandong Province, China. This retrospective study complied with the Declara-
tion of Helsinki and was approved, and the requirement for obtaining patient informed consent was waived, by 
the Research Ethics Committee of First Affiliated Hospital of Shandong First Medical University.
Figure 2.  Uric acid concentration and prevalence of hyperuricemia across age groups in 7782 men or 5506 
women. Uric acid concentration (a,b) and prevalence of hyperuricemia (c,d) in men (a,c) or women (b,d) 
across age groups. The participants in each gender were grouped as all participants (triangles) or participants 
with (filled circles) or without reduced renal function (open circles). Reduced renal function was defined as 
estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73  m2. Data represent mean ± SE. The difference in 
the prevalence of hyperuricemia among age groups was analyzed by the chi-square test. P < 0.001, P = 0.163, and 
P < 0.001 for all men, men with or without reduced renal function, respectively; and P < 0.001, P = 0.222, and 
P < 0.001 for all women, women with or without reduced renal function, respectively.
Table 4.  Prevalence of reduced renal function across age groups. a Reduced renal function was defined as 
estimated glomerular filtration rate < 60 mL/min/1.73 m2. b Chi-square test was used to compare the difference 
among age groups.
Prevalence of reduced renal function,a Number (%)
Age groups, years
P  valueb40–49 50–59 60–69 70–79 80–95
All (N = 13,288) 88 (1.7) 147 (3.4) 184 (7.4) 171 (19.1) 138 (33.8)  < 0.001
Men (N = 7782) 63 (2.1) 104 (4.1) 109 (7.5) 97 (18.2) 84 (31.5)  < 0.001
Women (N = 5506) 25 (1.1) 43 (2.5) 75 (7.1) 74 (20.3) 54 (38.3)  < 0.001
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Measurements and definitions. Blood pressure was measured in all participants by trained professionals 
using electronic sphygmomanometry. Blood pressure was measured in the right arm in the seated position with 
elbow and forearm resting on the armrest after the participant rested for 10  minutes31,32. Blood pressure was meas-
ured 2 times at 2-min intervals in all participants and mean systolic and diastolic blood pressure were recorded. 
Hypertension was defined as systolic blood pressure ≥ 140 mm Hg or diastolic blood pressure ≥ 90 mm  Hg33.
Venous blood samples were collected after an overnight fast (≥ 12 h). Serum uric acid concentration was meas-
ured by the uricaseperoxidase  method34. Hyperuricemia was defined as serum uric acid concentration ≥ 7 mg/
dL in men or ≥ 6 mg/dL in  women35. The estimated glomerular filtration rate (eGFR) was measured using an 
Olympus AU2700 automatic biochemical analyzer. eGFR ≥ 60 mL/min/1.73  m2 was regarded as conserved kidney 
function and eGFR < 60 mL/min/1.73  m2 was regarded as reduced renal  function36. Total cholesterol, triglyc-
erides, and fasting plasma glucose were measured using an Olympus AU2700 automatic biochemical analyzer.
Statistical analysis. All statistical analyses were performed using SPSS version 25.0 (IBM SPSS Statistics 
for Windows, Armonk, NY, International Business Machines Corporation). Age (Kolmogorov–Smirnov statistic, 
KS statistic, 0.094, P < 0.001), serum uric acid (KS statistic 0.035, P < 0.001), eGFR (KS statistic 0.038, P < 0.001), 
fasting plasma glucose (KS statistic 0.216, P < 0.001), total cholesterol (KS statistic 0.030, P < 0.001), body mass 
index (KS statistic 0.026, P < 0.001) and triglycerides (KS statistic 0.159, P < 0.001) were not normally distributed. 
Descriptive statistics were presented as median and interquartile range or numbers and percentages. The preva-
lence of hyperuricemia and reduced renal function were compared between participants of different ages by the 
chi-square test. Mann Whitney U and the Fisher’s exact test were used to test statistical differences between two 
groups. Only 6 participants were aged 90–95 years and they were combined with those aged 80–89 years to form 
an age group of 80–95 years. The associations between age and serum uric acid and between age and hyper-
uricemia were analyzed by linear regression and binary logistic regression, respectively, with or without adjust-
ing for reduced renal function (eGFR < 60 mL/min/1.73  m2) or other risk factors for hyperuricemia including 
age, sex, fasting glucose, hypertension, body mass index, total cholesterol, and triglycerides. The associations 
between eGFR and serum uric acid and between reduced renal function and hyperuricemia were analyzed using 
linear regression and binary logistic regression, respectively, with or with adjusting for age or other risk factors 
for hyperuricemia. In a sub-analysis, 728 participants with reduced renal function (eGFR < 60  mL/min/1.73 
 m2) were excluded. Sub-analyses were also conducted where eGFR was divided into three categories (≥ 60, < 60 
and ≥ 30, and < 30 mL/min/1.73  m2) or participants were grouped into men and women. A P value of < 0.05 was 
regarded as statistically significant.
Data availability
The datasets are available from the corresponding author on reasonable request.
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